Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.1952W HIGH $19.86
Volume
1.81 M
Value Traded
263.72 M
Short % Float
5.64%
Days to Cover
2.3
+0.66%Week
+81.15%1 Month
+88.75%3 Month
+177.7%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.23 B
EPS (TTM)
-0.96
P/E Ratio
-
Ent. Value
1.16 B
Total Shares
62.15 M
Float Shares
51.92 M
Insiders
16.46%
Institutions
26.36%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
SLN Catalyst Timeline
Dated clinical, regulatory and corporate events for Silence Therapeutics Plc American Depository Share
Catalyst Timeline
Dated clinical, regulatory & corporate events for Silence Therapeutics Plc American Depository Share
168Total events
9Upcoming
33Tier-1 (high impact)
2020 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲AcquisitionCorporate
Merck KGaA to acquire Silence Therapeutics for $20/ADS ($1.1B enterprise value)
▲Corporate ApprovalCorporate
Boards of Silence Therapeutics and Merck KGaA unanimously approved the transaction
▼Equity OfferingCorporate
Closing of upsized public offering of 14,907,407 ADSs at $13.50 per ADS, including full exercise of underwriters' option
▲Topline ReadoutdivesiranClinical Data
Positive topline results from Phase 2 SANRECO trial of divesiran in PV
polycythemia verasource ↗
●Oral PresentationdivesiranPresentation
Conference call and webcast to discuss topline results from Phase 2 SANRECO trial
polycythemia verasource ↗
▼Equity OfferingCorporate
Silence Therapeutics commences underwritten public offering of ~$150 million of American Depositary Shares
▲Primary Endpoint MetdivesiranClinical Data
Phase 2 SANRECO met primary endpoint: 88% clinical responders vs 19% placebo
polycythemia verasource ↗
▲Secondary Endpoint DatadivesiranClinical Data
Key secondary endpoint of phlebotomy rate met in Phase 2 SANRECO
polycythemia verasource ↗
▲Safety Data UpdatedivesiranClinical Data
Divesiran well tolerated with no new safety findings in Phase 2 SANRECO
polycythemia verasource ↗
●R&D DayPresentation
Investor conference call and webcast to discuss Phase 2 SANRECO topline results
◆Topline ReadoutdivesiranClinical Data
Topline results for Phase 2 SANRECO trial of divesiran in PV on-track for Q3 2026
polycythemia vera (PV)source ↗
◆Poster PresentationdivesiranPresentation
SANRECO Phase 1 abstract accepted for poster presentation at EHA 2026
polycythemia verasource ↗
▲Poster PresentationdivesiranPresentation
Follow-up and quality-of-life data from Phase 1 SANRECO study presented at EHA 2026
polycythemia verasource ↗
◆Oral PresentationPresentation
Silence Therapeutics to participate in Jefferies Global Healthcare Conference
▲Poster PresentationdivesiranPresentation
Follow-up Phase 1 SANRECO data presented at EHA 2026 Annual Congress
polycythemia verasource ↗
▲Enrollment CompletedivesiranTrial
Completed patient dosing in Phase 2 SANRECO trial of divesiran in PV
polycythemia verasource ↗
●PublicationPresentation
Preclinical study on TMPRSS6 silencing for MDS published in American Journal of Hematology
myelodysplastic syndromesource ↗
●Equity OfferingCorporate
SEC declared effective shelf registration statement relating to the offering
◆Oral PresentationSLN312Presentation
Phase 1 abstract accepted for late-breaking oral presentation at EAS Congress
dyslipidemiasource ↗
◆R&D DayPresentation
Silence Therapeutics to participate in H.C. Wainwright BioConnect Investor Conference
▲Late-BreakerSLN312Presentation
Phase 1 results for SLN312 (AZD1705) presented at EAS Congress
dyslipidemiasource ↗
◆Management ChangeCorporate
Craig Tooman ends employment as President, CEO and Board member by mutual consent
◆Enrollment CompletedivesiranTrial
SANRECO Phase 2 Study Complete Enrollment by Year-End 2025
Polycythemia Vera (PV)source ↗
▲Enrollment CompletedivesiranTrial
SANRECO Phase 2 study of divesiran in PV fully enrolled
polycythemia vera (PV)source ↗
▲Enrollment CompletedivesiranTrial
Completed patient enrollment in SANRECO Phase 2 study of divesiran for PV
polycythemia verasource ↗
▲Oral PresentationdivesiranPresentation
Presented Updated SANRECO Phase 1 Data at EHA 2025
Polycythemia Vera (PV)source ↗
◆Pipeline PrioritizationCorporate
Prioritizing investment in programs targeting rare conditions; zerlasiran Phase 3 outcomes study only with partner
◆Enrollment CompletedivesiranTrial
Anticipated full enrollment in SANRECO Phase 2 study of divesiran in PV by year-end 2025
polycythemia vera (PV)source ↗
▲Oral PresentationdivesiranPresentation
Additional Phase 1 data presented at ASH Annual Meeting
polycythemia verasource ↗
▲First Patient DoseddivesiranTrial
First subject dosed in Phase 2 portion of SANRECO study
polycythemia verasource ↗
▲Oral PresentationZerlasiran (SLN360)Presentation
Late-breaking Phase 2 zerlasiran data presented at AHA 2024
atherosclerotic cardiovascular disease (ASCVD) with high Lp(a)source ↗
▲PublicationZerlasiran (SLN360)Presentation
Phase 2 ALPACAR-360 results published in JAMA
atherosclerotic cardiovascular disease (ASCVD) with high Lp(a)source ↗
▲Topline ReadoutdivesiranClinical Data
Positive results from ongoing SANRECO Phase 1 study of divesiran in PV patients
polycythemia verasource ↗
●Oral PresentationdivesiranPresentation
Conference call and webcast to discuss SANRECO results
polycythemia verasource ↗
▲Milestone PaymentCorporate
Second undisclosed milestone achieved under Hansoh collaboration, triggering $2M payment
▲Topline ReadoutZerlasiran (SLN360)Clinical Data
Positive topline 48-week data from ALPACAR-360 phase 2 study of zerlasiran
elevated lipoprotein(a)source ↗
Past FDA Catalysts and PDUFA Decisions
How SLN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-12 | divesiran | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 48%
Micro Cap(rank 316 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Zerlasiran (SLN360) RNA therapyCompletedNCT04606602 | Hyperlipidemias | Phase 1 | COMPLETED | 70 | Aug 23, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every SLN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| divesiran Fast TrackOrphan | polycythemia vera | Phase 1 | 2026-06-11 | In the six months prior to treatment, the 21 enrolled patients required a total of 80 phlebotomies.; During the active treatment period, only 5 phlebotomies were required.; During the 16-week follow-up period after the final dose, only 4 phlebotomies were reported.; Among 14 patients with further follow-up data, the median time to first phlebotomy was 287 days.Read More | Inquiries: Silence Therapeutics plc Gem Hopkins, VP, Head of IR and Corporate Communications +1 (646) 637-3208 ir@silence-therapeutics.com Media Relations MKC Strategies Mary Conway +1 (516) 606-6545 mconway@mkcstrategieRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Griffiths Richard Ian10% Owner | Sell | 2,792,826 7,488,660 held | $0.00 | 08/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SLN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 0.8 % (60 %) | 33.31 M | 3.03 M |
SLN Institutional Ownership Trends
SLN Short Interest
Shares sold short, counted twice a month.
5.64%
Short % of Float
of tradable shares sold short
2.9M
Shares Sold Short
+15.3% vs prior count
2.3 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.3M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SLN ranks across every disease it competes in
Competitive Position is a premium feature
See how SLN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSLN News
-SLN
Oct 19, 2026▲ +125.6%on this news
Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset
Merck KGaA has announced its acquisition of Silence Therapeutics for $20 per ADS, totaling an enterprise value of $1.1 billion. This strategic move aims to enhance Merck's capabilities in treating rare diseases, particularly through the addition of Divesiran, a promising siRNA therapy for polycythemia vera. The acquisition is expected to close in Q1 2027, pending regulatory approvals.
Read more →-SLN
Oct 19, 2026▲ +125.6%on this news
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
Silence Therapeutics has entered into an agreement to be acquired by Merck KGaA for approximately $1.3 billion in an all-cash transaction. The deal offers Silence shareholders $20.00 per American Depositary Share, representing a 130% premium over the recent closing price. The acquisition aims to enhance Merck's capabilities in treating specialty and rare diseases, particularly through the development of Silence's Divesiran product candidate.
Read more →-SLN
Sep 2, 2026Silence Therapeutics to Participate in Three September Investor Conferences
Silence Therapeutics plc announced its participation in three investor conferences in September 2026. The company, known for developing siRNA therapies, will engage with investors through webcasts. This initiative aims to enhance visibility and foster investor relations.
Read more →-SLN
Aug 14, 2026Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs
Silence Therapeutics plc has successfully closed its upsized public offering of 14,907,407 American Depositary Shares at a price of $13.50 each. The offering included the full exercise of the underwriters' option to purchase additional shares, reflecting strong market interest. The proceeds from this offering will be utilized to advance the company's innovative siRNA therapies.
Read more →-SLN
Aug 12, 2026▼ -7.7%on this newsshared move
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
Silence Therapeutics has successfully priced its upsized public offering at $175 million. The offering includes 12,962,963 American Depositary Shares, priced at $13.50 each. This move reflects strong investor confidence and supports the company's ongoing development of novel siRNA therapies.
Read more →-SLN
Aug 10, 2026Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
Silence Therapeutics has initiated a public offering of approximately $150 million of its American Depositary Shares in the U.S. Each ADS represents three ordinary shares of the company. This move aims to bolster the company's resources for developing its innovative short interfering RNA therapies.
Read more →-SLN
Aug 10, 2026▲ +29.1%on this newsshared move
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
Silence Therapeutics has reported positive topline results from its Phase 2 SANRECO trial of divesiran, a novel siRNA therapy, in patients with polycythemia vera. The trial was randomized, double-blind, and placebo-controlled, involving 48 phlebotomy-dependent patients. These results support the potential of divesiran as a best-in-class treatment option.
Read more →-SLN
Aug 10, 2026▲ +29.1%on this newsshared move
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
Silence Therapeutics plc announced its financial and business results for Q2 2026, highlighting the progress of its first-in-class siRNA therapy, Divesiran, aimed at treating polycythemia vera and other blood disorders. The company presented follow-up data from the Phase 1 SANRECO trial at the European Hematology Association Annual Congress. Overall, the results indicate a positive trajectory for the company's clinical developments.
Read more →-SLN
Aug 9, 2026▲ +29.1%on this newsshared move
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
Silence Therapeutics plc has announced a conference call and webcast to discuss the topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera. The event is scheduled for August 10, 2026, at 8:00 a.m. EDT. This engagement aims to provide insights into the trial outcomes to investors and stakeholders.
Read more →-SLN
Jun 11, 2026▲ +11.3%on this news
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
Silence Therapeutics presented follow-up data on Divesiran at EHA 2026, showcasing its durable efficacy in treating Polycythemia Vera. The data suggests a potential best-in-class profile for the treatment. Further details on the study's outcomes and implications were not provided in the article.
Read more →-SLN
May 27, 2026Silence Therapeutics to Participate in Jefferies Global Healthcare Conference
Silence Therapeutics is set to participate in the Jefferies Global Healthcare Conference. This event will provide an opportunity for the company to engage with investors and discuss its strategic initiatives. Details regarding the specific topics to be covered during the conference have not been disclosed.
Read more →-SLN
May 12, 2026▼ -5.3%on this news
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
Silence Therapeutics is set to participate in the H.C. Wainwright BioConnect Investor Conference. This event provides a platform for the company to engage with investors and discuss its advancements in the biopharma sector. Further details regarding the presentation or topics of discussion have not been disclosed.
Read more →-SLN
May 7, 2026▼ -5.6%on this newsshared move
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
Silence Therapeutics plc reported its first quarter 2026 financial results, highlighting a reduced net loss of $15 million compared to $28.5 million in the same period last year. The company is advancing its siRNA therapies, with the Divesiran Phase 2 trial results expected in August 2026. Additionally, the SANRECO Phase 1 study has been accepted for presentation at the EHA 2026 Annual Congress.
Read more →-SLN
Mar 5, 2026Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
Silence Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting the progress of its Phase 2 SANRECO trial for divesiran, an innovative siRNA therapy for polycythemia vera. The trial is on track for topline results in the third quarter of 2026. The company emphasized its strong clinical execution and potential for future growth.
Read more →-SLN
Dec 15, 2025Silence Therapeutics Announces Leadership Changes
Silence Therapeutics plc has announced the departure of Craig Tooman from his role as President and CEO, effective December 14, 2025. Following his departure, Iain Ross, the current Chairman, will serve as interim leader. The company also plans to appoint an additional US-based Board member while reappointing James Ede Golightly to the Board. The company remains confident in its financial stability and future advancements within its siRNA therapeutic pipeline.
Read more →-SLN
Nov 6, 2025Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights SANRECO Phase 2 study of divesiran in polycythemia vera (PV) fully enrolled; topline results anticipated in 3Q 2026
Silence Therapeutics announced its financial results for Q3 2025, highlighting the full enrollment of its SANRECO Phase 2 study of divesiran for polycythemia vera. The company reported a cash position expected to fund operations into 2028 and anticipates topline results from the study in Q3 2026. Despite a net loss of $21 million, which is an improvement from the same period last year, Silence's management remains optimistic about its pipeline and operational execution.
Read more →-SLN
Oct 23, 2025Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV) Rapid Completion of Phase 2 Enrollment Reflects Ongoing Momentum for Divesiran as First-in-Class siRNA for PV
Silence Therapeutics has successfully completed patient enrollment in its SANRECO Phase 2 study of divesiran, a novel siRNA targeting TMPRSS6 for polycythemia vera (PV). The trial, which enrolled 48 participants, aims to evaluate divesiran's efficacy in maintaining hematocrit levels below 45% without the need for phlebotomies. Initial topline results are expected in the third quarter of 2026. The rapid enrollment highlights growing enthusiasm for this first-in-class treatment, which may meet significant unmet medical needs in the PV patient population.
Read more →-SLN
Aug 7, 2025Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights Presented Updated SANRECO Phase 1 Data at EHA 2025 Further Supporting Potential for Divesiran as First-in-Class siRNA in P
Silence Therapeutics has announced its financial results for the second quarter of 2025, highlighting encouraging updates on its SANRECO Phase 1 trial data for divesiran, which is being developed as a first-in-class siRNA therapy for polycythemia vera. The company is on track for full enrollment of the Phase 2 study by the end of the year and retains a cash runway that extends into 2028. However, Silence continues to face challenges with rising net losses and overall financial performance concerns.
Read more →-SLN
May 8, 2025Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights Company further extends cash guidance into 2028
Silence Therapeutics has announced its financial results for the first quarter of 2025, reporting a notable increase in net loss despite certain operational successes. The company extended its cash guidance into 2028 and is focused on advancing the SANRECO Phase 2 study of divesiran. However, financial performance shows a significant decline in revenue and an increased loss compared to the same quarter last year. The company continues to implement cost-saving initiatives to maintain its financial health while investing in its clinical programs.
Read more →-SLN
May 6, 2025Silence Therapeutics Welcomes Tim McInerney to Board of Directors
Silence Therapeutics has appointed Tim McInerney to its Board of Directors, effective immediately. McInerney brings over 30 years of experience in the pharmaceutical industry and healthcare investment banking. His appointment is seen as pivotal for guiding the company's transition into U.S. markets and enhancing its position as a leader in siRNA therapies. Additionally, board member James Ede-Golightly will retire at the upcoming Annual General Meeting in June 2025, marking a significant change in board composition.
Read more →About Silence Therapeutics Plc American Depository Share
Headquarters12 HAMMERSMITH GROVE, LONDON, W6 7AP
BIOPHARMAWATCH ELITE PLUS
Trade the next SLN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime